156 related articles for article (PubMed ID: 33837964)
21. False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab: Potential Pitfalls for the Misdiagnosis of B-Cell Neoplasms.
Chen PP; Tormey CA; Eisenbarth SC; Torres R; Richardson SS; Rinder HM; Smith BR; Siddon AJ
Am J Clin Pathol; 2019 Jan; 151(2):154-163. PubMed ID: 30307483
[TBL] [Abstract][Full Text] [Related]
22. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
[TBL] [Abstract][Full Text] [Related]
23. Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia.
Alsawah F; Benitez L; Choi S; Marini B; Perissinotti A; Skyles A; Burke P; Pettit K; Crouch A; Fox H; Bixby D
Blood Adv; 2019 Nov; 3(21):3333-3336. PubMed ID: 31698446
[TBL] [Abstract][Full Text] [Related]
24. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
[TBL] [Abstract][Full Text] [Related]
25. T-cell chronic lymphocytic leukemia/T-prolymphocytic leukemia: Experience with single agent bendamustine.
Thota NK; Sadashivudu G; Gandhi LV; Pragnya C; Roshni TP; Raghunadharao D
Indian J Cancer; 2015; 52(2):193-4. PubMed ID: 26853400
[No Abstract] [Full Text] [Related]
26. [Successful treatment of T-cell prolymphocytic leukemia (T-PLL) with fludarabine monophosphate].
Maeda A; Iwai K; Ishibashi T
Rinsho Ketsueki; 2009 Aug; 50(8):658-62. PubMed ID: 19915381
[TBL] [Abstract][Full Text] [Related]
27. T-cell prolymphocytic leukemia (T-PLL) with overlapping cytomorphological features with T-CLL and T-ALL: a case initially diagnosed by fine-needle aspiration cytology and immunocytochemistry.
Das DK; Pathan SK; Joneja M; Al-Musawi FA; John B; Mirza KR
Diagn Cytopathol; 2013 Apr; 41(4):360-5. PubMed ID: 21987484
[TBL] [Abstract][Full Text] [Related]
28. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Boidol B; Kornauth C; van der Kouwe E; Prutsch N; Kazianka L; Gültekin S; Hoermann G; Mayerhoefer ME; Hopfinger G; Hauswirth A; Panny M; Aretin MB; Hilgarth B; Sperr WR; Valent P; Simonitsch-Klupp I; Moriggl R; Merkel O; Kenner L; Jäger U; Kubicek S; Staber PB
Blood; 2017 Dec; 130(23):2499-2503. PubMed ID: 28972014
[TBL] [Abstract][Full Text] [Related]
29. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
[TBL] [Abstract][Full Text] [Related]
30. T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement.
Hsi AC; Robirds DH; Luo J; Kreisel FH; Frater JL; Nguyen TT
Am J Surg Pathol; 2014 Nov; 38(11):1468-83. PubMed ID: 25310835
[TBL] [Abstract][Full Text] [Related]
31. T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis.
Yoshioka Y; Nagao M; Saitoh T; Yoshioka S; Tsunemine H; Itoh K; Kodaka T; Takahashi T
J Clin Exp Hematop; 2015; 55(1):17-21. PubMed ID: 26106002
[TBL] [Abstract][Full Text] [Related]
32. Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene.
Sun S; Fang W
Biomed Pharmacother; 2020 Jun; 126():110107. PubMed ID: 32247279
[TBL] [Abstract][Full Text] [Related]
33. Broken heart by T-prolymphocytic leukemia.
Arranto C; Tzankov A
Blood; 2017 Aug; 130(5):691. PubMed ID: 28775161
[No Abstract] [Full Text] [Related]
34. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
Cao TM; Coutre SE
Hematology; 2003 Feb; 8(1):1-6. PubMed ID: 12623420
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab.
Ichikawa S; Fukuhara N; Saito K; Yokoyama H; Onodera K; Onishi Y; Ichinohasama R; Harigae H
Leuk Lymphoma; 2020 Jun; 61(6):1504-1507. PubMed ID: 31960738
[No Abstract] [Full Text] [Related]
36. Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia.
Gavini A; Telang GH; Olszewski AJ
Int J Hematol; 2012 Mar; 95(3):311-4. PubMed ID: 22290027
[TBL] [Abstract][Full Text] [Related]
37. Primary refractory T-cell prolymphocytic leukaemia treated with daily administration of Alemtuzumab plus high-dose methylprednisolone.
Renaudon-Smith E; Gribben JG; Agrawal SG
Eur J Haematol; 2014 Apr; 92(4):360-1. PubMed ID: 24329558
[No Abstract] [Full Text] [Related]
38. Infiltration of the thyroid gland by T-cell prolymphocytic leukemia.
Fujiwara K; Fukuhara T; Kitano H; Okazaki T
Thyroid; 2014 Aug; 24(8):1314-8. PubMed ID: 24762052
[TBL] [Abstract][Full Text] [Related]
39. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route.
Dearden CE; Khot A; Else M; Hamblin M; Grand E; Roy A; Hewamana S; Matutes E; Catovsky D
Blood; 2011 Nov; 118(22):5799-802. PubMed ID: 21948296
[TBL] [Abstract][Full Text] [Related]
40. T-cell Prolymphocytic Leukemia.
Sud A; Dearden C
Hematol Oncol Clin North Am; 2017 Apr; 31(2):273-283. PubMed ID: 28340878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
